Predictive Value of Proton Magnetic Resonance Spectroscopy in the Evaluation of Radiotherapy for Patients with Brain Metastases from Non-small Cell Lung Cancer
10.12007/j.issn.0258-4646.2017.12.009
- VernacularTitle:1H磁共振波谱在非小细胞肺癌脑转移放疗疗效评价中的预测价值
- Author:
Zheng HE
1
;
Guang LI
;
Hongwei ZHANG
;
Shuo ZHANG
Author Information
1. 中国医科大学附属第一医院放射治疗科
- Keywords:
proton magnetic resonance spectroscopy;
non-small cell lung cancer;
brain metastasis;
radiotherapy;
prognosis
- From:
Journal of China Medical University
2017;46(12):1095-1100
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the predictive value of proton magnetic resonance (MR) spectroscopy (1H-MRS) in evaluating the therapeutic efficacy of radiotherapy for patients with brain metastases from non-small cell lung cancer (NSCLC).Methods Fifty-six patients with brain metastases from NSCLC underwent 1H-MRS examination before treatment with stereotactic radiotherapy (SRT) in addition to whole brain radiotherapy (WBRT).The patients were divided into two groups according to their pretreatment choline-to-creatinine (Cho/Cr) ratio.The therapeutic efficacy of radiotherapy was compared between the two groups,and the prognostic value of 1H-MRS examination was analyzed.Results The median pretreatment Cho/Cr was 1.989.The overall survival rates at 1,3,and 5 years were 29.3％,0％,and 0％ in patients with higher pretreatment Cho/Cr,and 70.5％,22.3％,and 1.8％ in those with lower pretreatment Cho/Cr.The mean survival time was significantly lower in patients with higher pretreatment Cho/Cr than in those with lower pretreatment Cho/Cr (9.77 vs.24.67months,P ＜ 0.05).Conclusion Pretreatment Cho/Cr has a predictive value in the evaluation of radiotherapy for the treatment of NSCLC brain metastasis.Patients with higher pretreatment Cho/Cr have worse prognosis overall.
